Blockchain Registration Transaction Record

VERAXA Biotech Completes Business Combination, Begins Trading on Nasdaq

VERAXA Biotech (VRXA) completes business combination with Voyager Acquisition Corp., begins trading on Nasdaq. Focus on BiTAC platform for cancer therapies.

VERAXA Biotech Completes Business Combination, Begins Trading on Nasdaq

This news matters because it signals the public market entry of a biotech firm with a promising platform for next-generation cancer therapies. The BiTAC platform's ability to selectively target cancer cells could lead to more effective and less toxic treatments, addressing a critical need in oncology. The substantial financing secured also indicates strong investor confidence, which may accelerate the development of these therapies toward clinical trials and eventual patient access.

BlockchainDetails
Contract Address0xeA2912a8DA1CD48401b10cB283585874d98098F4
Transaction ID0xc2278370f8c5ecf4cd5e5b9e5c6eac4cf6197c58592f1833f909453ac1ac01e3
Account0xdBdE7c76e403a5923F3dD4F050Dbbf5c2077BB20
Chainpolygon-main
NewsRamp Digital FingerprintjoltJ8YT-8dae2bcd6c626de811c9ca5cc562ca5b